FOGER Switch Pro 30K Nixodine, reviewed: 19 ml of the thing that isn't nicotine

The devices reviewed on this site have competed on the tank — millilitres held, puffs claimed. This one competes on the fill.

The Switch Pro 30K Nixodine Pod reached US retail in late August. The hardware is FOGER’s pod-and-dock arrangement, unchanged. The fill is labelled as containing no conventional nicotine. “Nixodine” is reported as a 6-methylnicotine-related formulation at 5%, on a platform otherwise sold with 5% nicotine salt pods.

We do not test devices, and nothing below is a measurement. The specification comes from the one trade report of its US introduction we could find, dated 27 August 2026; retail and brand-site observations are of pages as they read on 3 September 2026.

The published specification

As reported at US introduction

Liquid capacity	19 ml, prefilled magnetic pod
Active ingredient	'Nixodine', a 6-methylnicotine-related formulation
Stated strength	5%, labelled as containing no conventional nicotine
Coil and modes	1.0 ohm dual mesh, Normal and Boost
Power	200 mAh in the pod, 850 mAh in the reusable dock, USB-C
Headline claim	Up to 30,000 puffs on Normal, up to 18,000 on Boost
Reported price	Around $24.99; Kentucky-only listings noted, rollout unconfirmed
US federal regulatory status	As of the 27 August report, no public information indicating FDA marketing authorisation

What the 5% is actually measuring

Five per cent nicotine salt means 50 mg of nicotine per millilitre. On a 6-methylnicotine product 5% is only a label figure, and the one published independent check — Erythropel and colleagues, JAMA, 7 August 2024 — found 6-MN liquids labelled 5%, or 50 mg/g, held 5.8 to 6.3 mg/g, 87 to 88 per cent below label; we found no such check of this pod. “No conventional nicotine” describes composition, not pharmacology.

The name belongs to an ingredient, not to FOGER. Bonguard Naturals, of Phoenix, announced a nonclinical study of Nixodine-S on 24 August 2026, describing it as a patented flavourless (S)-6-methylnicotine concentrate sold to manufacturers as a volume-for-volume nicotine alternative. The trade report names no supplier for the FOGER pod, so the shared name is only that. The release adds that products containing it are for people 21 and over who already use tobacco or nicotine, human trials have not been completed, and its claims are “not evaluated or approved by the U.S. Food and Drug Administration”.

The architecture, and what the shelf does to it

Pod-and-dock is the format we assessed as the category’s own answer to the disposal problem, and on paper this is a clean example: reusable dock, USB-C charging, the durable part outliving the liquid.

Two things complicate it. Per the report the pod carries its own 200 mAh cell, so each consumable discards a lithium battery, and the dock is a second one to retire later. Then the economics. On fogervape.com, one of the two online retailers FOGER’s 22 August notice names as authorised, the nicotine version listed on 3 September at $21.99 for a kit with the dock and $16.99 for a refill pod, with a replacement battery — the dock — at $12.00. Five dollars between refilling and buying the whole device again is a thin margin to refill on.

Where the assessment turns

The report states that as of its publication no public information indicates the pod has received FDA marketing authorisation, and that classification of 6-MN formulations remains under development. Neither half extends further than it says: an absent authorisation record is not a refusal, and an unsettled federal classification is not an exemption. Reading the device as outside the rules reads in what the sources do not support.

The verification trail is thin. FOGER’s official site listed four items on 3 September — the Switch Pro disposable at 5%, its pod, the BIT 35K at 5% and the charging device — with no Nixodine entry among them. On the same day fogervape.com, an authorised retailer, listed its Switch Pro pods at 5% salt nicotine and showed no nicotine-free option on any page we read. The Nixodine pod is plainly on sale elsewhere: a US-warehouse retailer outside FOGER’s authorised list listed the 19 ml Nixodine pod in stock at $15.79 that day. Brand pages lag distribution, and their silence is not evidence of a fake — but of the channels FOGER vouches for, the two we could read were not carrying it, and we could not establish whether elementvape.com, the third, does. And this is a brand whose own 22 August notice warned that anti-counterfeit verification results shown on foger.com before that date were not its own and are not reliable.

Pros and cons

The ledger on published specification

Pros

A reusable dock charged over USB-C, so the durable electronics outlive the liquid
1.0 ohm dual mesh and two named power modes, more than the segment usually prints
The label identifies the fill as something other than conventional nicotine, rather than substituting silently

Cons

Per the report the pod holds its own 200 mAh cell, so every consumable discards a lithium battery
On the nicotine version, a $16.99 refill pod against $21.99 for a complete kit is a thin reason to refill
The report gives no test method or draw length behind 30,000 or 18,000 puffs, so neither can be checked
A 5% strength on an analogue is a label figure; the one published check of such liquids found them 87 to 88 per cent below it
Price and Kentucky-only reach are flagged as unconfirmed in the trade report itself

Verdict

The hardware deserves more credit than the product. Human trials are not complete and the federal classification has not landed — California’s AB 3218 has defined nicotine to include “nicotine analogs” since 1 January 2025. Neither gap is a verdict against it, and both are reasons not to buy on a number that only looks familiar.

The small print at the foot of this site says our subject matter contains nicotine; on this device, per the label as reported, it does not — a mismatch about composition only. 6-methylnicotine is a nicotine analogue and pharmacologically active; the receptor figures in Bonguard’s release are for its own Nixodine-S, which no source we have ties to this pod, and its authors say they do not extend to 6-MN generally or other analogue products. Nicotine is addictive; no human data yet fixes this analogue’s dependence profile, and nothing above says it is less habit-forming than nicotine. Read the footer as covering the category, and this product as adults-only regardless — 21 and over in the United States, 18 and over in most other markets, and not for non-smokers.